From owner-sci-resources@net.bio.net Wed Sep 06 23:00:00 1995 Path: biosci!biosci!not-for-mail From: BIOSCI Administrator Newsgroups: bionet.sci-resources Subject: NIH GUIDE - PA-95-086 - V24(32) 09/01/95 Date: 6 Sep 1995 19:14:28 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 397 Sender: biohelp@net.bio.net Approved: biosci-moderator@net.bio.net Distribution: world Message-ID: <42lki4$dhk@net.bio.net> NNTP-Posting-Host: net.bio.net $$XID RFA PA95086 PA-95-086 P1O1 *************************************** GRANDPARENTING: ISSUES FOR AGING RESEARCH NIH GUIDE, Volume 24, Number 32, September 1, 1995 PA NUMBER: PA-95-086 P.T. 34; K.W. 0710010, 0417000 National Institute on Aging PURPOSE The National Institute on Aging (NIA) invites qualified researchers to submit applications for research projects grants to investigate the nature and influence of grandparenting for individual older people, families, and the larger society. This Program Announcement (PA) further specifies, but does not replace, the ongoing NIA PA on Health and Effective Functioning in the Middle and Later Years (PA-93-076). Five broad areas of aging research are identified; 1. Grandparents in an aging society: e.g., macrosocial studies, demographic analyses, and economic research; 2. Grandparents in the family unit: e.g., family relationships, caregiving, family change; 3. Grandparents in the network of aging social, community, and legal affiliations: e.g., churches, aging support and advocacy groups, neighborhood organizations, school-affiliated groups. 4. Grandparents as aging individuals: e.g., roles, expectations, and identity of grandparents; 5. Special populations and grandparents in special circumstances: e.g., minority families, custodial grandparents, great-grandparents, and impoverished families. HEALTHY PEOPLE The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This PA, Grandparenting: Issues for Aging Research, is related to the priority area of age-related objectives for older adults. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-004730-01) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202/512-1800). ELIGIBILITY REQUIREMENTS Applications for research grants may be submitted by foreign and domestic, public and private, for-profit and non-profit organizations, such as universities, colleges, hospitals, laboratories, units of State and local governments, and eligible agencies of the Federal government. Foreign institutions are not eligible for First Independent Research Support and Transition (FIRST) (R29) awards. Racial/ethnic minority individuals, women and persons with disabilities are encouraged to apply. MECHANISM OF SUPPORT The primary mechanisms for support of this initiative are the research project grant (R01) and the FIRST award (R29). Because the nature and scope of the research proposed in response to this PA may vary, it is anticipated that the size of awards will vary also. RESEARCH OBJECTIVES Grandparents have always been acknowledged as influential in family life and grandparenthood has been a marker of aging within society. However, only within the last half century has increasing longevity meant that most older people live long enough to become grandparents, that these elders continue as robust and active in family life and society, and that grandparenthood is now a status and role affecting middle-aged adults through the oldest old. Estimates as early as the 1970s show that 70 percent of elders are grandparents, but little is known about the ages, gender, social composition, and psychosocial impact of grandparenting on individuals, families, and the society. Aging research is therefore needed on a range of topics relevant to the health and well-being of older parents who are also grandparents. Most prior research on grandparents has focused on their impact on younger generations (e.g. the effect of grandparents as caregivers on the development of young children) or without a clear basis in theories of aging or a social gerontology perspective. For example, it is known that grandparents provide care for other family members, particularly grandchildren, either on a part-time, day care basis or as a custodial caregiver. In 1990, 4.2 million children lived with grandparents and in one third of these homes, the child's parents were absent. However, the relevance of these arrangements for older people themselves is increasingly a topic for aging research. Methodologically, grandparenting research has relied principally on descriptive methodologies and convenience samples to call attention to the grandparenting role. Such approaches are often appropriate and necessary for an emerging topic, but further studies need to be developed that may include comparison groups of grandparents and persons of comparable age, gender, social class, ethnicity, or who are without grandchildren or childless; that test theoretically-based models; or make use of more complex analysis techniques. National data and analysis of existing data sets may be fruitful. Methodologies that move beyond narrative or description are encouraged. Applications appropriate to this PA are not restricted to any specific discipline, but should be focused on well-articulated theoretical approaches and methodologies in aging to elucidate issues specifically related to grandparents or grandparenting roles. Research is encouraged that specifies conceptual approaches to grandparenting within aging research and would give the field a strong base of scientific methodologies and data. Researchers are urged to design innovative strategies for this emerging area of study that may include qualitative approaches, use of available data sets, or targeted survey strategies. Of particular value would be studies comparing older age groups because the grandparenting role may vary with the age and aging-related circumstances of the older individual. When supported by empirical data from prior research, applications that include intervention projects may be submitted. Examples of Research Topics Studies of grandparents in society may involve a range of societal level issues and methodologies. For example: o Studies may be based on demographic or macrosocial methodologies and population projections of the number and characteristics of grandparents; health economic research and/or data analyses of intergenerational exchanges, (e.g., exchange of goods, services, and time across the life course) particularly because becoming a grandparent may modify such exchanges; the impact of societal changes (e.g., inheritance, mandatory family leave) on family interactions; work roles and labor force impact of older people because they may affect grandparenting and grandparents decisions about employment or family leave to care for grandchildren; political concerns and activities of grandparents including legal issues of visitation and custodial rights; patterns of housing and transportation arrangements and needs related to grandparenting; public assistance for care of grandchildren. o Organizational membership and a wide range of social affiliations, particularly those that are focused on older people, are influenced by the entry of a member into the role of being a grandparent. Studies of these may include research on newly- emerging recreational events and intergenerational camps, classes on grandparenting and how to write a "history" for ones grandchildren, church-based or school-sponsored intergenerational activities. For those grandparents encountering problems with custodianship, there is now a wide network of support groups and information services that have not been studied. Also unexplored are the use of aging and health services as they might be affected by grandparents' need to care for their own health as well as that of dependent children. o Within the family, grandparenting research may focus on the role of older people in the aging and intergenerational family unit. This may include studies of family relationships and attitudes over time; grandparents as caregivers and receivers of care; studies of grandparents' behaviors and attitudes as influences on socialization of younger family members, family well-being, and affection; grandparenting as affected by family change such as divorce (of any generation), geographic and economic mobility, remarriage, retirement; studies of the effects of family disruptions, intergenerational conflict, hostility, or isolation on the physical and overall well-being of grandparents; relationship between the "middle" generation (adult child) and their parents (the grandparents) for the grandparenting role and level of involvement with a grandchild. o Research on grandparents as aging individuals includes study of aspects of the role and status of grandparenting as part of an individual's identity as an older person as well as possible relationship to level of physical functioning and well-being. Studies in this area might consider how becoming and being a grandparent affects self-perceptions, changes in self-expectations with grandparenthood; overall psychological well-being; self concept related to "off time" and "on time" grandparenthood (becoming a grandparent at a very early or older age versus at an expected age) in age comparative studies; sense of control over or frustration with grandparenting obligations. o Special populations and special circumstances for grandparents suggest need for research on those issues that may create strain or stress for aging families, or that may result in greater family involvement of grandparents. For example: 1. Ethnic and cultural minority families with patterns of and expectations for grandparenting that are uniquely tied to cultural patterns; grandparents in immigrant or refugee families; families with language barriers between generations. 2. The oldest old are recently recognized as a special population, yet almost no research exists exploring the relationships among four or five generations of family members (great-grandparents), nor on the increasing number of grandparents who are caregivers for their aging parents as well as younger children. 3. The special circumstances, the needs and contributions, of grandparents who serve as parent surrogates (grandparents rearing grandchildren) particularly when the parental absence is due to substance abuse, AIDs, incarceration, or desertion. 4. Poverty and its consequences for grandparents, which affect elders through multi-generational household living arrangements, public assistance, or other strategies for shared resources among generations. The role of grandparents in such circumstances is a neglected area of aging research. 5. Non-family intergenerational relationships are often patterned on grandparenting. New forms of intergenerational programs include combined-age day care, foster grandparents, and community-based or school-initiated "proms" and interactions. Also needed is research on grandparents organizations such as voluntary associations and/or advocacy groups. INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of the NIH that women and members of minority groups and their subpopulations must be included in all NIH supported biomedical and behavioral research projects involving human subjects, unless a clear and compelling rationale and justification is provided that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This new policy results >From the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43) and supersedes and strengthens the previous policies (Concerning the Inclusion of Women in Study Populations, and Concerning the Inclusion of Minorities in Study Populations) which have been in effect since 1990. The new policy contains some new provisions that are substantially different from the 1990 policies. All investigators proposing research involving human subjects should read the "NIH Guidelines For Inclusion of Women and Minorities as Subjects in Clinical Research", which have been published in the Federal Register of March 28, 1994 (FR 59 14508-14513), and reprinted in the NIH GUIDE FOR GRANTS AND CONTRACT of March 18, 1994, Volume 23, Number 11. Investigators also may obtain copies of the policy from the program staff listed under INQUIRIES. Program staff may also provide additional relevant information concerning the policy. (NOTE: When the proposed study involves a gender specific study or a single or limited number of minority population groups, this should also be stated to inform reviewers.) APPLICATION PROCEDURES Researchers who are considering preparing an application in response to this program announcement are invited, but not required, to discuss their project and possible grant mechanisms with NIA staff in advance of formal submission. This can be done by telephone, mail, or email. The research grant application form PHS 398 (rev. 5/95) is to be used in applying for these grants and will be accepted at the standard application deadlines as indicated in the application kit. These forms are available at most institutional offices of sponsored research; from the Office of Grants Information, Division of Research Grants, National Institutes of Health, 6701 Rockledge Drive, Room 3032 - MSC-7762, Bethesda, MD 20892-7762, telephone 301/435-0714; and >From the program administrator listed under INQUIRIES. The PA title and number must be typed on line 2 of the face page of the application form and the YES box must be marked. FIRST (R29) award applications must include at least three sealed letters of reference attached to the face page of the original application. FIRST award applications submitted without the required number of reference letters will be considered incomplete and will be returned without review. The original and five copies must be mailed to: DIVISION OF RESEARCH GRANTS NATIONAL INSTITUTES OF HEALTH 6701 ROCKLEDGE DRIVE, ROOM 1040-MSC 7710 BETHESDA, MD 20892-7710 BETHESDA, MD 20817 (for courier/overnight service) REVIEW CONSIDERATIONS Applications will be assigned on the basis of established Public Health Service referral guidelines. Applications will be reviewed for scientific and technical merit in accordance with the standard NIH peer review procedures. Applications that are complete and responsive to the program announcement will be evaluated for scientific and technical merit by an appropriate peer review group convened in accordance with the standard NIH peer review procedures. As part of the initial merit review, all applications will receive a written critique and undergo a process in which only those applications deemed to have the highest scientific merit, generally the top half of applications under review, will be discussed, assigned a priority score, and receive a second level review by the appropriate national advisory council or board. Review Criteria o scientific, technical, or medical significance and originality of proposed research; o appropriateness and adequacy of the experimental approach and methodology proposed to carry out the research; o qualifications and research experience of the Principal Investigator and staff, particularly, but not exclusively, in the area of the proposed research; o availability of the resources necessary to perform the research; o appropriateness of the proposed budget and duration in relation to the proposed research; o adequacy of plans to include both genders and minorities and their subgroups as appropriate for the scientific goals of the research. Plans for the recruitment and retention of subjects will also be evaluated. o the initial review group will also examine the proposed study for the protection of human subjects and the safety of the research environment. Following scientific-technical review, the applications will receive a second-level review by the appropriate national advisory council. AWARD CRITERIA Applications will compete for available funds with all other approved applications. The following will be considered in making funding decisions: o Quality of the proposed project as determined by peer review o Availability of funds o Program balance among research areas of the program announcement INQUIRIES Written and telephone inquiries are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Direct inquiries regarding programmatic issues to: Katrina W. Johnson, Ph.D. Behavioral And Social Research Program National Institute on Aging Gateway Building, Room 533 Bethesda, MD 20892 Telephone: (301) 402-4156 For copy of announcement: (301) 496-3136 (press 2) FAX: (301) 402-0051 Email: Katrina_Johnson@NIH.GOV Direct inquiries regarding fiscal matters to: Ms. Vicki Maurer Grants Management Office National Institute on Aging Gateway Building, Room 2N212 Bethesda, MD 20892 Telephone: (301) 496-1472 Email: Vicki_Maurer@NIH.GOV The National Institute of Mental Health (NIMH) supports basic, clinical, and services research on topics that are relevant to the study of grandparenting. Inquiries about NIMH's sponsorship of these activities may be directed to: Della M. Hann, Ph.D. Division of Neuroscience and Behavioral Science National Institute of Mental Health 5600 Fishers Lane, Room 11C-16 Rockville, MD 20857 Telephone: (301) 443-3942 FAX: (301) 443-4822 Email: dh31d@NIH.GOV AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.866, Aging Research. Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. The PHS strongly encourages all grant and contract recipients to provide a smoke-free workplace and promote the non-use of all tobacco products. In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routine education, library, day care, health care or early childhood development services are provided to children. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people. From owner-sci-resources@net.bio.net Wed Sep 06 23:00:00 1995 Path: biosci!biosci!not-for-mail From: BIOSCI Administrator Newsgroups: bionet.sci-resources Subject: NIH Guide, vol. 24, no. 32, pt. 1of1, 1 September 1995 Date: 6 Sep 1995 19:14:21 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 682 Sender: biohelp@net.bio.net Approved: biosci-moderator@net.bio.net Distribution: world Message-ID: <42lkht$dh9@net.bio.net> NNTP-Posting-Host: net.bio.net $$XID NIHGUIDE 19950901 V24N32 P1O1 ************************************ X-comment: RFAs described: CA-95-018, PA-95-086, PA-95-087, PA-95-088 X-URL: gopher://gopher.nih.gov:70/11/res/nih-guide/guide-files/95.09.01 NIH GUIDE - Vol. 24, No. 32 - September 1, 1995 $$INDEX BEGIN ******************************************************* NOTICES $$INDEX N1 ********************************************************** NIH GUIDE PUBLICATION DATES $$INDEX N2 ********************************************************** NIDCD SUPPLEMENTAL INFORMATION TO THE NIH CAREER DEVELOPMENT (K AWARD) PROGRAM ANNOUNCEMENTS National Institute on Deafness and Other Communication Disorders INDEX: DEAFNESS, OTHER COMMUNICATIONS DISORDERS $$INDEX N3 ********************************************************** NIDA SUPPLEMENTAL INFORMATION TO THE NIH CAREER DEVELOPMENT (K AWARDS) PROGRAM ANNOUNCEMENTS National Institute on Drug Abuse INDEX: DRUG ABUSE $$INDEX N4 ********************************************************** NEI MENTORED CLINICAL SCIENTIST DEVELOPMENT AWARD National Eye Institute INDEX: EYE NOTICES OF AVAILABILITY (RFPs/RFAs/PAs) $$INDEX R1 12/08/95 ************************************************* CANCER PREVENTION RESEARCH UNITS (RFA CA-95-018) National Cancer Institute INDEX: CANCER $$INDEX P1 ********************************************************** GRANDPARENTING: ISSUES FOR AGING RESEARCH (PA-95-086) National Institute on Aging INDEX: AGING $$INDEX P2 ********************************************************** METABOLIC ENGINEERING (PA-95-087) National Institute of General Medical Sciences National Institute of Diabetes and Digestive and Kidney Diseases INDEX: GENERAL MEDICAL SCIENCES; DIABETES, DIGESTIVE, KIDNEY DISEASES $$INDEX P3 ********************************************************** ETIOLOGY AND PREVENTION OF GALLSTONES DURING PERIODS OF HIGH RISK (PA-95-088) National Institute of Diabetes and Digestive and Kidney Diseases INDEX: DIABETES, DIGESTIVE, KIDNEY DISEASES THIS PUBLICATION IS AVAILABLE ELECTRONICALLY VIA BITNET OR INTERNET, BY SUBSCRIPTION, AND IS ALSO ON THE NIH GOPHER (GOPHER.NIH.GOV). ALTERNATIVE ACCESS IS THROUGH THE NIH GRANT LINE USING A PERSONAL COMPUTER (DATA LINE 301/402-2221); CONTACT DR. JOHN JAMES AT 301/435- 0692 FOR DETAILS. THE PHS STRONGLY ENCOURAGES ALL GRANT AND CONTRACT RECIPIENTS TO PROVIDE A SMOKE-FREE WORKPLACE AND PROMOTE THE NON-USE OF ALL TOBACCO PRODUCTS. IN ADDITION, PUBLIC LAW 103-227, THE PRO-CHILDREN ACT OF 1994, PROHIBITS SMOKING IN CERTAIN FACILITIES (OR IN SOME CASES, ANY PORTION OF A FACILITY) IN WHICH REGULAR OR ROUTINE EDUCATION, LIBRARY, DAY CARE, HEALTH CARE OR EARLY CHILDHOOD DEVELOPMENT SERVICES ARE PROVIDED TO CHILDREN. THIS IS CONSISTENT WITH THE PHS MISSION TO PROTECT AND ADVANCE THE PHYSICAL AND MENTAL HEALTH OF THE AMERICAN PEOPLE. THE DIVISION OF RESEARCH GRANTS (DRG) HAS MOVED TO A NEW LOCATION. ALL COMPETING GRANT APPLICATIONS SUBMITTED TO THE NATIONAL INSTITUTES OF HEALTH MUST BE SENT TO: DIVISION OF RESEARCH GRANTS NATIONAL INSTITUTES OF HEALTH 6701 ROCKLEDGE DRIVE, ROOM 1040 - MSC 7710 BETHESDA, MD 20892-7710 BETHESDA, MD 20817 (for express/courier service) $$INDEX END ********************************************************* NOTICES $$N1 BEGIN ********************************************************** THE NIH GUIDE FOR GRANT AND CONTRACTS WILL NOT BE PUBLISHED ON SEPTEMBER 8 AND SPETEMBER 15. THE NEXT ISSUE OF THE NIH GUIDE WILL BE ON SEPTEMBER 22. $$N1 END ************************************************************ $$N2 BEGIN ********************************************************** NIDCD SUPPLEMENTAL INFORMATION TO THE NIH CAREER DEVELOPMENT (K AWARD) PROGRAM ANNOUNCEMENTS NIH GUIDE, Volume 24, Number 32, September 1, 1995 P.T. 34; K.W. 0710030, 0785035 National Institute on Deafness and Other Communication Disorders This supplement to the National Institutes of Health (NIH) career development (K Award) program announcements (NIH Guide, Volume 24, Number 15, April 28, 1995) provides additional information for potential applicants on the unique guidelines and award provisions of the career development programs offered by the National Institute on Deafness and Other Communication Disorders (NIDCD). The NIH program announcements addressed in this supplement are the following: o PA-95-050: Independent Scientist Award (K02) o PA-95-053: Mentored Clinical Scientist Development Award (K08) All provisions contained in these program announcements apply to applications submitted to the NIDCD, except as noted in this supplemental announcement. The Independent Scientist Award replaces the NIDCD Research Career Development Award (K04). The Mentored Clinical Scientist Development Award replaces the NIDCD Clinical Investigator Development Award, also coded K08. GENERAL INFORMATION FOR NIDCD CAREER DEVELOPMENT AWARD APPLICANTS The NIDCD particularly encourages K02 and K08 applications from individuals who wish to develop their research careers in underserved and priority areas of NIDCD's biomedical and behavioral research mission in hearing, balance, smell, taste, voice, speech and language. These research areas are enumerated in the National Strategic Research Plans published by the NIDCD. INDEPENDENT SCIENTIST AWARD (K02) The K02 award provides five years of salary support to recently independent scientists, having research support at the time the award is made, who demonstrate the need for a period of intensive research focus (a minimum of 75 percent effort) in order to foster their career development as outstanding contributors in the biomedical and behavioral scientific areas supported by the NIDCD. It is the policy of the NIDCD not to renew a K02 award beyond its original project period of five years. A. ELIGIBILITY REQUIREMENTS The applicant must hold a doctoral degree and have demonstrated independent research accomplishments at the time of application. Applicants will normally have had at least five years of postdoctoral research experience, but not yet be considered well established in the research area of the application. B. ALLOWABLE COSTS 1. Salary The NIDCD provides up to $50,000 per year of salary support, based on the established salary structure at the applicant's institution for staff members of equivalent qualifications, rank and responsibilities. When requested, the NIDCD will award fringe benefits, based on the sponsoring institution's established policies, on the proportion of the applicant's salary provided by the K02 award. 2. Research Development Support Applicants for the K02 must document within the application that they will have peer-reviewed research support at the time of the award, or are awaiting a funding decision on a submitted research grant application. The NIDCD will not provide support for incidental expenses related to research and career development, such as tuition, fees, books, publication costs or travel to scientific meetings. MENTORED CLINICAL SCIENTIST DEVELOPMENT AWARD (K08) The purpose of the K08 award is to foster the development of clinically trained professionals into independent investigators in the biomedical and behavioral scientific mission areas of the NIDCD. The K08 provides for three, four or five years of mentored research experience and specialized study, tailored to individual needs. At least 75 percent of the awardee's full-time professional effort must be devoted to this program. The primary mentor should be in the same institution(s) as the applicant. A. ELIGIBILITY REQUIREMENTS The applicant must hold a clinical doctoral degree and have completed his/her postgraduate clinical training prior to application. Furthermore, the applicant must have had at least one full year, and preferably two full years, of postdoctoral-level research experience before submitting a K08 application. Individuals holding positions of senior academic rank, such as associate professor or professor, or the equivalent in nonacademic settings, at the time of application are not eligible for a K08 award. Individuals who are current or former principal investigators on NIH research project grants (R01, R29 or P01) or center grants are also not eligible. Recipients of an Academic Research Enhancement Award (R15) or an NIDCD Small Grant (R03) are eligible for a K08 award. Subsequent successful application for a research project grant that results in an award will require that the K08 be terminated. B. ALLOWABLE COSTS 1. Salary The NIDCD contribution to the salary of the K08 recipient is geared to the institutional base salary as follows: Institutional Base Salary NIDCD Contribution o Up to $50,000 100% of institutional base o $50,001 to $67,000 $50,000 o $67,001 and over 75% of institutional base salary, up to $75,000 Awardees are eligible for fringe benefits on the portion of the applicant's salary provided by the K08 award. The amount of allowable benefits will be based on the sponsoring institution's established policies. Previously, the NIDCD limited its salary support for K08 awardees to $50,000. The new policy described here will not be applied retroactively. 2. Research Development Support The NIDCD provides up to $80,000 over the course of a five-year award for the research development expenses outlined in PA-95-053. Awards of three years and four years provide up to $48,000 and $64,000, respectively, over the course of the funding period. Up to $30,000 may be budgeted in a given year for these expenses, when well justified. C. APPLICATION PROCEDURES 1. Career Development Plan In addition to the guidelines stated in PA-95-053, the applicant must describe a plan to complete a graduate-level didactic course in biostatistics and research design during the first year of the award, if such a course is not part of the applicant's background. 2. Letters of Reference Three sealed letters of reference, including a letter from the mentor, must be included with the application. 3. Environment and Institutional Commitment The sponsoring institution must provide a statement of its commitment to the career development of the applicant within the body of the application, including an assurance that he/she will be able to devote the requisite 75 percent effort to the career development plan described in the application. INQUIRIES Inquiries are encouraged, particularly during the planning phase of the application. Direct inquiries to: Daniel A. Sklare, Ph.D. Division of Human Communication National Institute on Deafness and Other Communication Disorders 6120 Executive Boulevard, Room 400C - MSC-7180 Bethesda, MD 20892-7180 Telephone: (301) 496-1804 FAX: (301) 402-6251 Email: daniel_sklare@nih.gov $$N2 END ************************************************************ $$N3 BEGIN ********************************************************** NIDA SUPPLEMENTAL INFORMATION TO THE NIH CAREER DEVELOPMENT (K AWARDS) PROGRAM ANNOUNCEMENTS NIH GUIDE, Volume 24, Number 32, September 1, 1995 P.T. 34; K.W. 0710030, 0785035 National Institute on Drug Abuse PURPOSE This supplement to the National Institutes of Health (NIH) career development program announcements (K Awards) is intended to provide additional information for potential applicants on the unique aspects of National Institute on Drug Abuse (NIDA) career development programs. The NIH program announcements addressed in this supplement are the following: o PA-95-049: Mentored Research Scientist Development Award (K01) o PA-95-050: Independent Scientist Award (K02) o PA-95-051: Senior Scientist Award (K05) o PA-95-053: Mentored Clinical Scientist Development Award (K08) o PA-95-054: Mentored Clinical Scientists Development Program Award (K12) The guidelines and procedures outlined in the NIH program announcements must be followed closely when an application is being prepared for submission to the NIDA. Particular attention should be paid to the purpose of each award mechanism, its eligibility requirements, and its review considerations. For example, the K12 program mechanism will accommodate the research career pathways of clinicians in fields related to NIDA's research mission. Under the K12 award, support will be provided to eligible institutions to develop or enhance research training opportunities for clinicians selected by the institution, who are training for careers as independent researchers in the drug abuse and addiction area of biomedical and behavioral research. The K12 mechanism is designed to foster the development of advanced clinical research skills through didactic training and the mentored research experience. Potential applicants should contact appropriate NIDA staff for further information. Supplemental Information for NIDA Applicants The RESEARCH OBJECTIVES section of each program announcement should be followed carefully when preparing an application. Note especially that differences exist among various NIH Institutes regarding allowable costs. The unique aspects of NIDA allowable costs, specifically in the categories of salary (all Ks) and research development support (K01, K08), are listed below. Salary The NIDA contribution to the Principal Investigator's salary is geared to the institutional base salary as follows: Institutional Base Salary NIDA Contribution o Up to $45,000 100% of institutional base o $45,001 to $60,000 $45,000 o $60,001 and over 75% of institutional base salary, up to $75,000 Research Development Support (K01, K08) The NIDA allows for funds up to $50,000 per year for research related costs outlined in each program announcement. INQUIRIES Inquiries are encouraged, particularly during the planning phase of the application. Direct inquiries to: NIDA Institute Coordinator Timothy P. Condon, Ph.D. Office of Science Policy and Communications National Institute on Drug Abuse 5600 Fishers Lane, Room 10A-55 Rockville, MD 20857 Telephone: (301) 443-6072 FAX: (301) 443-6277 Email: TC52X@NIH.GOV $$N3 END ************************************************************ $$N4 BEGIN ********************************************************** NEI MENTORED CLINICAL SCIENTIST DEVELOPMENT AWARD NIH GUIDE, Volume 24, Number 32, September 1, 1995 P.T. 34; K.W. 0710030, 0785035 National Eye Institute Specific provisions of the National Eye Institute administration of the NIH Mentored Clinical Scientist Development Award (K08) are amended as follows: Disciplines: The NEI wants to alert clinical investigators that it has broadened the guidelines of its program to include the disciplines of biostatistics and epidemiology. Candidate Salary Requests: Although PHS grant recipients are subject to a legislatively imposed salary cap (currently $125,000), the NEI itself does not impose any special cap on salary requests. The salary request should be reasonable and conform to the established, consistently applied policy of the applicant institution for other staff members of equivalent qualifications, rank, and responsibilities. The salary request should reflect no more than the percentage of time actually devoted to the project. Research Development Support: The NEI will allow up to $20,000 per year for the research project requirements, e.g., technical personnel costs, supplies, equipment, principal investigator's travel, and tuition, fees, and books related to the career development program. Salary for mentors, secretarial and administrative assistance is not allowed. INQUIRIES Inquiries are encouraged, particularly during the planning phase of the application. Direct inquiries to: Maria Y. Giovanni, Ph.D. Research Training Officer National Eye Institute 6120 Executive Boulevard, Room 350 - MSC 7164 Bethesda, MD 20892-7164 Telephone: (301) 496-0484 FAX: 301-402-0528 Email: myg@eps.nei.nih.gov $$N4 END ************************************************************ NOTICES OF AVAILABILITY (RFPs/RFAs/PAs) $$R1 BEGIN CA-95-018 FULL-TEXT ************************************** CANCER PREVENTION RESEARCH UNITS NIH GUIDE, Volume 24, Number 32, September 1, 1995 RFA AVAILABLE: CA-95-018 P.T. 34; K.W. 0715035, 0745027, 0745035, 0710030, 0502017 National Cancer Institute Letter of Intent Receipt Date: October 3, 1995 Application Receipt Date: December 8, 1995 PURPOSE The Cancer Control Science Program within the Division of Cancer Prevention and Control (DCPC) of the National Cancer Institute (NCI), seeks to stimulate the establishment of programs in primary and secondary cancer prevention, health promotion, and prevention services research. The objective of this Request for Applications (RFA) is to reestablish efforts to develop a group of multidisciplinary cancer prevention research programs as a national long-term resource in cancer prevention and control research. These programs, entitled Cancer Prevention Research Units (CPRUs), will conduct primary and secondary prevention, health promotion, and preventive services research aimed at (1) developing new intervention approaches in all areas of cancer prevention and/or (2) applying proven or state-of-the-science interventions in tobacco control, nutrition, and screening identified in Healthy People 2000: National Health Promotion and Disease Prevention Objectives. The CPRU should foster a multidisciplinary environment of scientists interacting closely within the research program. These can include experienced investigators in relevant fields and disciplines, such as disease prevention and control, medicine, public health, health education, health promotion, epidemiology, nutrition sciences, health policy and economics, health services research, behavioral and social sciences, community organization, communications, and biostatistics. Additionally, the CPRU Program is intended to hasten the establishment of high quality multidisciplinary research programs, and will be supported by the NCI Program Project Grant (P01) mechanism. Traditionally, the program project approach has resulted in the development of long-term research programs investigating important research problems, has fostered interdisciplinary and inter-institutional collaborations, and has led to new insights and progress in meeting research goals. The intent of this RFA is to achieve the same results in cancer prevention and control research. Approximately $5 million per year in total costs will be committed for five years to specifically fund applications that are submitted in response to this RFA. It is anticipated that up to four awards will be made. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, Cancer Prevention Research Units (CPRU), is related to the priority area of cancer. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-512-1800). INQUIRIES The RFA, which describes the research objectives, application procedures, review considerations and award criteria for this solicitation, may be obtained electronically through the NIH Grant Line (data line 301-402-2221) and the NIH GOPHER (gopher.nih.gov) and by mail and email from the program contact listed below. Sherry Mills, M.D., M.P.H. Division of Cancer Prevention and Control National Cancer Institute 6130 Executive Boulevard, Suite 330 - MSC 7346 Bethesda, MD 20892-7346 Telephone: (301) 496-8520 FAX: (301) 402-0816 Email: millsS@dcpceps.nci.nih.gov $$R1 END ************************************************************ $$P1 BEGIN PA-95-086 FULL-TEXT ************************************** GRANDPARENTING: ISSUES FOR AGING RESEARCH NIH GUIDE, Volume 24, Number 32, September 1, 1995 PA AVAILABLE: PA-95-086 P.T. 34; K.W. 0710010, 0417000 National Institute on Aging PURPOSE The National Institute on Aging (NIA) invites qualified researchers to submit applications for research project grants (R01 and R29) to investigate the nature and influence of grandparenting for individual older people, families, and the larger society. This Program Announcement further specifies but does not replace the on-going NIA Program Announcement on Health and Effective Functioning in the Middle and Later Years (PA-93-076). Five broad areas of aging research are identified; (1) Grandparents in an aging society: e.g., macrosocial studies, demographic analyses, and economic research; (2) Grandparents in the family unit: e.g., family relationships, caregiving, family change; (3) Grandparents in the network of aging social, community, and legal affiliations: e.g., churches, aging support and advocacy groups, neighborhood organizations, school-affiliated groups; (4) Grandparents as aging individuals: e.g., roles, expectations, and identity of grandparents; (5) Special populations and grandparents in special circumstances: e.g., minority families, custodial grandparents, great-grandparents, and impoverished families. HEALTHY PEOPLE The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This PA, Grandparenting: Issues for Aging Research, is related to the priority area of age-related objectives for older adults. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-004730-01) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202/512-1800). INQUIRIES The PA, which describes the research objectives, application procedures, review considerations, and award criteria for this solicitation, may be obtained electronically through the NIH Grant Line (data line 301/402-2221) and the NIH GOPHER (gopher.nih.gov), and by mail and email from the program contact listed below. Katrina W. Johnson, Ph.D. Behavioral And Social Research Program National Institute on Aging Gateway Building, Room 533 Bethesda, MD 20892 Telephone: (301) 402-4156; For copy of announcement: (301) 496-3136 (press 2) FAX: (301) 402-0051 Email: Katrina_Johnson@NIH.GOV' $$P1 END ************************************************************ $$P2 BEGIN PA-95-087 FULL-TEXT ************************************** METABOLIC ENGINEERING NIH GUIDE, Volume 24, Number 32, September 1, 1995 PA AVAILABLE: PA-95-087 P.T. 34; K.W. 0765020, 1002019, 1002004, 0710055 National Institute of General Medical Sciences National Institute of Diabetes and Digestive and Kidney Diseases PURPOSE The purpose of this program announcement (PA) is to encourage research that will expand the conceptual and experimental basis of metabolic engineering. Basic research that contributes to a quantitative understanding of the integration and control of genetic, catalytic, and transport processes that comprise metabolism is encouraged, as is research to create techniques which facilitate the exploitation of metabolic processes for biomedical uses. Research support mechanisms include research project grants (R01), First Independent Research Support and Transition (FIRST) (R29) awards, and program project grants (P01). INQUIRIES This PA, which describes the research objectives, application procedures, review considerations, and award criteria for this program, may be obtained electronically through the NIH Grant line (data line 301-402-2221) and the NIH GOPHER (gopher.nih.gov), and by mail and email from the program staff listed below. Warren Jones, Ph.D. Division of Pharmacology, Physiology, and Biological Chemistry National Institute of General Medical Sciences 45 Center Drive, MSC 6200 Bethesda, MD 20892-6200 Telephone: (301) 594-5938 FAX: (301) 480-2802 Email: JONESW@gm1.nigms.nih.gov Catherine McKeon, Ph.D. Division of Diabetes, Endocrinology and Metabolic Diseases National Institute of Diabetes and Digestive and Kidney Diseases 45 Center Drive,, Room 5AN-18B - MSC 6600 Bethesda, MD 20892-6600 Telephone: (301) 594-8810 FAX: (301) 480-3503 Email: McKeonC@ep.niddk.nih.gov $$P2 END ************************************************************ $$P3 BEGIN PA-95-088 FULL-TEXT ************************************** ETIOLOGY AND PREVENTION OF GALLSTONES DURING PERIODS OF HIGH RISK NIH GUIDE, Volume 24, Number 32, September 1, 1995 PA AVAILABLE: PA-95-088 P.T. 34; K.W. 0715085, 0755030, 0745027 National Institute of Diabetes and Digestive and Kidney Diseases PURPOSE The purpose of this Program Announcement (PA) is to encourage research into the etiology and prevention of gallstone formation during periods of high risk. Research project grant (R01) and First Independent Research Support and Transition (FIRST) (R29) award applications are encouraged that range from careful prospective studies of the mechanisms of gallstone formation in humans to clinical trials aimed at the prevention of gallstones. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," in a PHS-led national activity for setting priority areas. This PA, Etiology and Prevention of Gallstones During Periods of High Risk, is related to the priority areas of chronic disabling conditions and nutrition. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-512-1800). INQUIRIES The PA, which describes the research objectives, application procedures, review considerations, and award criteria for this program, may be obtained electronically through the NIH Grant Line (data line 301-402-2221) and the NIH GOPHER (gopher.nih.gov), and by mail and email from the program contact listed below. James Everhart, M.D., M.P.H. Division of Digestive Diseases and Nutrition National Institute of Diabetes and Digestive and Kidney Diseases 45 Center Drive, Room 6AN-12J - MSC 6600 Bethesda, MD 20892-6600 Telephone: (301) 594-8878 FAX: (301) 480-8300 Email: vjy@cu.nih.gov $$P3 END ************************************************************ From owner-sci-resources@net.bio.net Wed Sep 06 23:00:00 1995 Path: biosci!biosci!not-for-mail From: BIOSCI Administrator Newsgroups: bionet.sci-resources Subject: NSF - Summary of new documents on STIS - 3 September 1995 Date: 6 Sep 1995 19:14:14 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 197 Sender: biohelp@net.bio.net Approved: biosci-moderator@net.bio.net Distribution: world Message-ID: <42lkhm$dh3@net.bio.net> NNTP-Posting-Host: net.bio.net This message contains a summary of the documents added to the NSF STIS system in the previous week. Reference material concerning STIS follows the summary. ------------------------------------------------------------------------ ** NEW DOCUMENTS ON STIS ** Document Type: Graduate Fellowships Title: FMAPINFO Application Information form with instructions File size (bytes): STIS Filename: fmapinfo.txt Also available: fmapinfo.pdf fmapinfo.doc Title: FMCRSRPT Course Report Form File size (bytes): STIS Filename: fmcrsrpt.txt Also available: fmcrsrpt.doc fmcrsrpt.pdf Title: FMFELAPP Fellowship Application Form with instructions File size (bytes): STIS Filename: fmfelapp.txt Also available: fmfelapp.doc fmfelapp.pdf Title: FMGENINS General Instructions & Inventory List File size (bytes): STIS Filename: fmgenins.txt Also available: fmgenins.doc fmgenins.pdf Title: FMGINFO Information about Program Announcement and Application Materials File size (bytes): STIS Filename: fmgfinfo.txt Title: FMGFKITD Instructions for MS Word for Windows 6.0 Forms Kit File size (bytes): STIS Filename: fmgfkitd.txt Also available: fmgfkitd.doc Title: FMGFKITP Instructions for Adobe Acrobat PDF Forms Kit File size (bytes): STIS Filename: fmgfkitp.txt Also available: fmgfkitp.pdf Title: FMGPA Undergraduate GPA Form File size (bytes): STIS Filename: fmgpa.txt Also available: fmgpa.doc fmgpa.pdf Title: FMGRE GRE Information and GRE Candidate Identification Form File size (bytes): STIS Filename: fmgre.txt Also available: fmgre.doc fmgre.pdf Title: FMPRERES Previous Research Experience Form File size (bytes): STIS Filename: fmpreres.txt Also available: fmpreres.pdf fmpreres.doc Title: FMPROPLN Proposed Plan of Study or Research Form File size (bytes): STIS Filename: fmpropln.txt Also available: fmpropln.doc fmpropln.pdf Title: FMREFRPT Reference Report Form File size (bytes): STIS Filename: fmrefrpt.txt Also available: fmrefrpt.doc fmrefrpt.pdf Title: FMTRSREQ Transcript Request Form File size (bytes): STIS Filename: fmtrsreq.txt Also available: fmtrsreq.doc fmtrsreq.pdf Document Type: News Title: FS-50809 August/September Feature Service File size (bytes): STIS Filename: fs50809.txt Title: Media Tipsheet August 25, 1995 File size (bytes): STIS Filename: tip5825.txt Document Type: Press Release Title: PC MAY BE MAJOR HOME TECHNOLOGY OF THE ‘90S File size (bytes): STIS Filename: pr9557.txt Document Type: Program Guideline Title: NSF 95-132 - Ridge Inter-Disciplinary Global Experiments File size (bytes): STIS Filename: nsf95132.txt Document Type: Recruit Title: Personnel Staffing and Classification Specialist File size (bytes): STIS Filename: vgs95120.txt Document Type: Report Title: Number 09--NSF OIG Semiannual Report to the Congresss File size (bytes): STIS Filename: oig09.txt Title: Number 10--NSF OIG Semiannual Report to the Congress File size (bytes): STIS Filename: oig10.txt ------------------------------------------------------------------------ ** UPDATES TO EXISTING STIS DOCUMENTS ** Document Type: General Publication Title: NSF 95-28 Grant Proposal Guide (FORMS KIT INSTRUCTIONS) File size (bytes): 34371 STIS Filename: nsf9528.txt Also available: nsf9528.doc Document Type: Graduate Fellowships Title: NSF 95-121 NSF Graduate Fellowship Program File size (bytes): 33592 STIS Filename: nsf95121.txt Also available: nsf95121.wp5 Document Type: Phone Book Title: NSF Alpha Telephone Directory File size (bytes): 108736 STIS Filename: phnalpha.txt Also available: phnalpha.dlm Title: NSF Organization Directory File size (bytes): 105129 STIS Filename: phnorg.txt Document Type: Program Guideline Title: NSF 95-127 INSTITUTION-WIDE REFORM OF UNDERGRADUATE EDUCATION IN SCIENCE, MATHEMATICS, ENGINEERING AND TECHNOLOGY File size (bytes): PROGRESS BASED ON PERFORMANCE STIS Filename: nsf95127.txt (NSF) Document Type: STIS Title: Document Types on STIS File size (bytes): 1909 STIS Filename: stistype.txt Title: Document Types on STIS File size (bytes): 1909 STIS Filename: stistype.txt ------------------------------------------------------------------------ ** FOR YOUR REFERENCE ** ------------------------------------------------------------------------ HOW TO OBTAIN DOCUMENTS The above files can be retrieved in electronic form using the STIS system. If you don't know how to use STIS, send an E-mail message to stisinfo@nsf.gov (Internet). You will receive a copy of the STIS flyer via E-mail. If you are already using STIS, you can use the information above to retrieve these files: Documents via E-mail: Send a message to stisserve@nsf.gov (Internet). Use the "STIS Filename" shown above in the "get" command. For example, to retrieve stistype.txt, the text of your message should be as follows: get stistype.txt Anonymous FTP: FTP to stis.nsf.gov. Use the "STIS Filename" shown above to retrieve a file. For example, to retrieve stistype.txt, you would enter: ftp> get stistype.txt WAIS or Gopher: Do a word search on the filename as shown in the summary. If you want a *printed* copy of a document: Send your name and postal mailing address, and the document title and number to "pubs@nsf.gov" (Internet). If you have problems with the above procedures: Send a message to "stis@nsf.gov" (Internet). From owner-sci-resources@net.bio.net Wed Sep 06 23:00:00 1995 Path: biosci!biosci!not-for-mail From: BIOSCI Administrator Newsgroups: bionet.sci-resources Subject: NIH GUIDE - RFA CA-95-018 - V24(32) 09/01/95 Date: 6 Sep 1995 19:14:33 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 468 Sender: biohelp@net.bio.net Approved: biosci-moderator@net.bio.net Distribution: world Message-ID: <42lki9$di0@net.bio.net> NNTP-Posting-Host: net.bio.net $$XID RFA CA95018 CA-95-018 P1O1 *************************************** CANCER PREVENTION RESEARCH UNITS NIH GUIDE, Volume 24, Number 32, September 1, 1995 RFA: CA-95-018 P.T. 34; K.W. 0715035, 0745027, 0745035, 0710030, 0502017 National Cancer Institute Letter of Intent Receipt Date: October 3, 1995 Application Receipt Date: December 8, 1995 PURPOSE The Cancer Control Science Program within the Division of Cancer Prevention and Control (DCPC) of the National Cancer Institute (NCI), seeks to stimulate the establishment of programs in primary and secondary cancer prevention, health promotion and prevention services research. The objective of this Request For Applications (RFA) is to reestablish efforts to develop a group of multidisciplinary cancer prevention research programs as a national long-term resource in cancer prevention and control research. These programs, entitled Cancer Prevention Research Units (CPRUs), will conduct primary and secondary prevention, health promotion, and preventive services research aimed at (1) developing new intervention approaches in all areas of cancer prevention and/or (2) applying proven or state-of-the-science interventions in tobacco control, nutrition, and screening identified in Healthy People 2000: National Health Promotion and Disease Prevention Objectives. The CPRU should foster a multidisciplinary environment of scientists interacting closely within the research program. These can include experienced investigators in relevant fields and disciplines, such as disease prevention and control, medicine, public health, health education, health promotion, epidemiology, nutrition sciences, health policy and economics, health services research, behavioral and social sciences, community organization, communications, and biostatistics. Additionally, the CPRU Program is intended to hasten the establishment of high quality multidisciplinary research programs, and will be supported by the NCI Program Project Grant (P01) mechanism. Traditionally, the program project approach has resulted in the development of long-term research programs investigating important research problems, has fostered interdisciplinary and inter-institutional collaborations, and has led to new insights and progress in meeting research goals. The intent of this RFA is to achieve the same results in cancer prevention and control research. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, Cancer Prevention Research Units (CPRU), is related to the priority area of cancer. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-512-1800). ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic, non-profit and for-profit organizations, public and private entities such as universities, colleges, hospitals, laboratories, units of state and local governments. Applications from minority and women investigators are encouraged. Foreign institutions are ineligible to apply. Racial/ethnic minority individuals, women, and persons with disabilities are encouraged to apply as Principal Investigators. Any of the three current NCI-funded CPRU P01 grantee institutions (Fred Hutchinson Comprehensive Cancer Center, University of Minnesota, University of Rhode Island) are ineligible to apply. MECHANISM OF SUPPORT This RFA will use the National Institutes of Health (NIH) Research program project grant mechanism (P01). The CPRU must consist of a minimum of three projects. P01 grant applications must comply with Guidelines for Program Project Grant of the National Cancer Institute, which have been revised in 1995. Copies can be obtained >From the program director listed below. Responsibility for the planning, direction, and execution of the proposed project will be solely that of the applicant. The total project period for applications submitted in response to the present RFA may not exceed five years. The anticipated award date is August 1, 1996. This is a one-time solicitation. Future unsolicited competing continuation applications will compete with the investigator-initiated applications and will be reviewed according to customary NIH peer review procedures. FUNDS AVAILABLE Approximately $5 million, per year, in total costs for five years will be committed to specifically fund applications which are submitted in response to this RFA. It is anticipated that up to four awards will be made. This funding level is dependent on the receipt of a sufficient number of applications of high scientific merit. Although this program is provided for in the financial plans of the NCI, the award of grants pursuant to this RFA is also contingent upon the availability of funds for this purpose. Funds for each CPRU will be capped at $1.25 million total annual costs. RESEARCH OBJECTIVES The CPRU Program is an attempt to stimulate the rapid establishment of long-term programs in cancer primary and secondary prevention, health promotion and prevention services research. These CPRUs must focus on problem- or program oriented cancer prevention research studies, will require long-term support and involve multidisciplinary participation, and, for cancer control Phase IV ad V studies, need to have access to defined populations in order to measure the population impact of any cancer control activities. The CPRU concept envisions a multidisciplinary environment of scientists interacting closely in the research program. These are experienced investigators in relevant fields and disciplines, such as disease prevention and control, medicine, public health, health education, health promotion, epidemiology, nutrition, nutrition sciences, early detection, chemoprevention, health policy and economics, health services research, behavioral and social sciences, community organization, communications, and biostatistics. Linkages between occupational and environmental exposure and cancer control will strongly be encouraged. It is not necessarily the intent of this RFA to create a CPRU in a location where a critical mass of resources and qualified investigators does not exist, but rather to redirect, focus, and recruit institutions - such as cancer centers - already having highly competent investigators into cancer prevention and control research. At present, there exists a shortage of comparable research units which are devoted to cancer prevention. a. Themes The CPRU requires a major program theme to focus the research effort and form the basis for multidisciplinary and inter-institutional collaboration and synergism. Themes previously used in large cancer prevention and control program project grants have varied, from single cancer site (e.g., breast cancer prevention and control), to risk factor focus (e.g., tobacco reduction in a managed care setting), to intervention focus (e.g., adherence to cancer control regimens). b. Developmental Projects Peer-reviewed developmental, pilot, or feasibility projects are permitted and encouraged in the CPRU. These short-term projects (usually 1-2 years) are particularly appropriate in conjunction with long-term prevention intervention studies in communities or other settings as a means to continually test new ideas, improve procedures, ensure rapid integration into ongoing studies, and allow a means to endure successful and optimal completion of major program project objectives. Occasionally, projects may be renewable with appropriate justification and scientific merit review by an institutional process. These projects are analogous to the variety of short-term experiments that a laboratory scientist can conduct in following up new leads rapidly as findings emerge from in-vitro studies within the general program theme of the grant. c. Components of a Cancer Prevention Research Unit The CPRU should include the following components or elements: o A qualified leader with an appropriate time commitment; o A multidisciplinary group of prevention oriented scientists who can conduct this type of research; o A rationale for why the CPRU method is appropriate for the intended research program; o An emphasis on cancer prevention or health promotion and prevention services research as noted above; o One major, specific research theme to focus the CPRU efforts, and at least three research projects within the theme area; o Specific, although optional, developmental projects for up to 15 percent of the total costs of the CPRU; o Research or administrative core units or shared resources necessary to more efficiently conduct the research program. These are optional; and o Evidence of collaborative arrangements with the appropriate organizations or population groups necessary to conduct the studies In summary, investigators, especially in the nation's cancer centers, are encouraged to form multidisciplinary, collaborative teams to address research issues of critical importance to cancer prevention and control. These teams should focus on a single theme and may consider developmental research projects as part of their overall response and research DCPC supports research with an emphasis on studies to identify, evaluate, and implement techniques and approaches for primary and secondary prevention of cancer. Those studies may include specific cancers such as breast or more general areas of prevention research such as cancer prevention and screening among special populations, chemoprevention, tobacco prevention among children and adolescents, diet and nutrition, and early detection. The CPRU should focus on problem- or program-oriented cancer prevention research studies and involve multidisciplinary participation. Investigators may choose from the full range of scientific approaches. Many Phase II studies may contribute to the design, implementation, or evaluation of future Phase III-V studies, e.g., validation of surveys or program materials for use in the proposed population groups, testing of recruitment or compliance procedures for participants, or testing of biochemical or dietary methods for objectively monitoring participation in studies. The proposed research may occur in a variety of settings ranging from the laboratory to communities, schools, health departments, managed care organizations, and worksites. The Cancer Control Science Program supports the development and testing of primary and secondary intervention strategies to modify personal, social, and life-style factors known to contribute to the development and/or increased risk of cancer. This research includes the health promotion sciences, special population studies, and applications research, as well as implementation studies for proven technologies such as breast and cervical screening. Research on cost-effective health services is encouraged, since it impacts on obtaining optimal application of the interventions in community settings. Interventions aimed at reducing cancer incidence related to smoking and tobacco use is also emphasized (e.g., Phase IV and V research in achieving the goals of the Year 2000 for smoking). Linkages between laboratory research and applied cancer prevention and control research are encouraged, i.e. laboratory research in support of these prevention studies. Basic laboratory research without this linkage will be deemed non-responsive to the RFA. Investigators must address the specific aims and hypotheses, the background and significance of the proposed work, results of any preliminary studies, experimental design and methods, any theoretical concepts that underlie the intervention research, human subjects involvement and protection, and relevant literature. SPECIAL REQUIREMENTS Applicants will be expected to present a budget for the overall projects for five years. Up to 15 percent of the CPRU total costs may be devoted to two to three developmental/pilot projects. Initially these projects will be reviewed by the NCI initial review group according to the criteria listed under the REVIEW CONSIDERATIONS section of this RFA. Renewal or follow-on developmental projects will be funded pending appropriate justification and scientific merit review by an institutional process. For future years, institutionally reviewed new developmental projects awarded under the parent grant must have the prior approval of the NCI Program Director. INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of the NIH that women and members of minority groups and their sub-populations must be included in all NIH-supported biomedical and behavioral research projects involving human subjects, unless a clear and compelling rationale and justification is provided that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This new policy results >From the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43) and supersedes and strengthens the previous policies (Concerning the Inclusion of Women in Study Populations, and Concerning the Inclusion of Minorities in Study Populations) which have been in effect since 1990. The new policy contains some new provisions that are substantially different from the 1990 policies. All investigators proposing research involving human subjects should read the "NIH Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research," which was reprinted in the Federal Register of March 28, 1994 (59 FR 14508-14513) to correct typesetting errors in the earlier publication, and reprinted in the NIH GUIDE FOR GRANTS AND CONTRACTS of March 18, 1994, Volume 23, Number 11. Investigators may obtain copies from these sources or from the program staff or contact person listed under INQUIRIES. Program staff may also provide additional relevant information concerning the policy. LETTER OF INTENT Prospective applicants are asked to submit, by October 3, 1995, a letter of intent that includes a descriptive title of the proposed research, the name, address, and telephone number of the Principal Investigator, the identities of other key personnel and participating institutions, and the number and title of this RFA in response to which the application may be submitted. Although a letter of intent is not required, is not binding, and does not enter into the review of subsequent applications, the information that it contains allows NCI staff to estimate the potential review workload and to avoid conflict of interest in the review. The letter of intent is to be sent to: Sherry Mills, M.D., M.P.H. Division of Cancer Prevention and Control National Cancer Institute Executive Plaza North, Suite 330 6130 Executive Boulevard, MSC 7346 Bethesda, MD 20892-7346 Telephone: (301) 496-8520 FAX: (301) 402-0816 Email: millsS@dcpceps.nci.nih.gov APPLICATION PROCEDURES The research grant application form PHS 398 (rev. 5/95) is to be used in applying for these grants. These forms are available at most institutional offices of sponsored research or may be obtained from the Office of Grants Information, Division of Research Grants, National Institutes of Health, 6701 Rockledge Drive, Room 3032, MSC 7762, Bethesda, MD 20892-7762, telephone (301) 435-0714. The RFA label available in the PHS 398 (rev. 5/95) application form must be affixed to the bottom of the face page of the application. Failure to use this label could result in delayed processing of the application such that it may not reach the review committee in time for review. In addition, the RFA title and number must be typed on line 2 of the face page of the application form and the YES box must be marked. All requirements with regard to type, size, page limitations, appendix material, etc., must be followed or applications will be returned without review. The completed application and three copies must be sent or delivered to: Division of Research Grants National Institutes of Health 6701 Rockledge Drive, Room 1040 - MSC 7710 Bethesda, MD 20892-7710 Bethesda, MD 20817 (for express/courier service) At the time of submission two additional copies of the application must be sent to: Ms. Toby Friedberg Division of Extramural Activities National Cancer Institute Executive Plaza North, Suite 636 6130 Executive Boulevard - MSC 7405 Bethesda, MD 20892-7405 (if using U.S. Postal Service) Rockville, MD 20852 (If hand delivered or delivery service) Applications must be received by December 8, 1995. If an application is received after that date, it will be returned to the applicant without review. The Division of Research Grants (DRG) will not accept any application in response to this RFA that is essentially the same as one currently pending initial review, unless the applicant withdraws the pending application. The DRG will not accept any application that is essentially the same as one already reviewed. This does not preclude the submission of substantial revisions of applications already reviewed, but such applications must include an introduction addressing the previous critique. REVIEW CONSIDERATIONS Upon receipt, applications will be reviewed for completeness by DRG and responsiveness by the NCI. Incomplete applications will be returned to the applicant without further consideration. If NCI staff find that the application is not responsive to the RFA, it will be returned without further consideration. Applications that are complete and responsive to the RFA will be evaluated for scientific and technical merit by convened in accordance with NIH peer review procedures. As part of the initial merit review, all applications will receive a written critique and undergo a process in which only those applications deemed to have the highest scientific merit, generally the top half of applications under review, will be discussed, assigned a priority score, and receive a second level review by the National Cancer Advisory Board. Review criteria for P01 grant applications are contained within the Guidelines for Program Project Grant of the National Cancer Institute, which have been revised in 1995 and may be obtained from the program director listed under INQUIRIES. Review criteria for developmental projects include, but are not limited to: 1. scientific and technical significance and originality of proposed research; 2. appropriateness and adequacy of the experimental design and methodology proposed to carry out the research; 3. qualifications and research experience of the Principal Investigators and staff, particularly, but not exclusively, in the area of the proposed research; 4. availability of the resources necessary to perform the research; 5. appropriateness of the proposed budget and duration in relation to the proposed research 6. o adequacy of plans to include both sexes and minorities and their subgroups as appropriate for the scientific goals of the research. Plans for the recruitment and retention of subjects will also be evaluated. The initial review group will critically examine the submitted budget and will recommend an appropriate budget and period of support. They will also examine the provisions for the protection of human and animal subjects, the safety of the research environment, and conformance with the NIH Guidelines for the Inclusion of women and Minorities as subjects in Clinical Research. AWARD CRITERIA Applications found to have significant and substantial merit will be considered for funding by the following criteria: o Scientific merit as determined by peer review o Availability of funds o Programmatic priorities INQUIRIES Inquiries concerning this RFA are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Direct inquiries regarding programmatic issues to: Sherry Mills, M.D., M.P.H. Division of Cancer Prevention and Control National Cancer Institute Executive Plaza North, Suite 330 6130 Executive Boulevard - MSC 7346 Bethesda, MD 20892-7346 Telephone: (301) 496-8520 Email: millsS@dcpceps.nci.nih.gov Direct inquiries regarding fiscal matters to: Ms. Marian Focke Grants Administration Branch National Cancer Institute Executive Plaza South, Suite 243 Bethesda, MD 20892 Telephone: (301) 496-7800, ext. 246 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.399, Cancer Control. Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74 and 92. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. The PHS strongly encourages all grant recipients to provide a smoke-free workplace and promote the non-use of all tobacco products. In addition, Public Law 103-227, The Pro-children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routine education, library, day care, health care or early childhood development services are provided to children. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people. From owner-sci-resources@net.bio.net Wed Sep 06 23:00:00 1995 Path: biosci!biosci!not-for-mail From: BIOSCI Administrator Newsgroups: bionet.sci-resources Subject: NIH GUIDE - PA-95-088 - V24(32) 09/01/95 Date: 6 Sep 1995 19:14:38 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 232 Sender: biohelp@net.bio.net Approved: biosci-moderator@net.bio.net Distribution: world Message-ID: <42lkie$dib@net.bio.net> NNTP-Posting-Host: net.bio.net $$XID RFA PA95088 PA-95-088 P1O1 *************************************** ETIOLOGY AND PREVENTION OF GALLSTONES DURING PERIODS OF HIGH RISK NIH GUIDE, Volume 24, Number 32, September 1, 1995 PA NUMBER: PA-95-088 P.T. 34; K.W. 0715085, 0755030, 0745027 National Institute of Diabetes and Digestive and Kidney Diseases PURPOSE The purpose of this Program Announcement (PA) is to encourage research into the etiology and prevention of gallstone formation during periods of high risk. Applications are encouraged that range >From careful prospective studies of the mechanisms of gallstone formation in humans to clinical trials aimed at the prevention of gallstones. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," in a PHS-led national activity for setting priority areas. This PA, Etiology and Prevention of Gallstones During Periods of High Risk, is related to the priority areas of chronic disabling conditions and nutrition. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-512-1800). ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic and foreign for-profit and non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of State and local governments, and eligible agencies of the Federal government. Foreign institutions are not eligible for First Independent Research Support and Transition (FIRST) (R29) awards. Applications from minority individuals and women are encouraged. MECHANISM OF SUPPORT Support for this Program Announcement will be through the NIH research project grant (R01) and FIRST awards (R29). RESEARCH OBJECTIVES Gallstones are a highly prevalent condition, responsible for over half a million cholecystectomies in the U.S. each year. It has been suggested that persons with recently formed gallstones are at more risk of symptomatic illness than persons who have had gallstones for years. The following are among the situations that acutely increase the risk of gallstones: (1) substantial, rapid weight loss, (2) pregnancy, (3) total parenteral nutrition, (4) major abdominal surgery, (5) treatment with the somatostatin analogue octreotide, and (6) the period following dissolution of gallstones. Prevention of gallstone formation in these situations could eliminate a substantial portion of symptomatic gallstone disease. Despite the general acceptance that gallstone formation is caused by defects in hepatic cholesterol processing, nucleation in the gallbladder, and gallbladder motility, these and other factors have not been systematically and prospectively evaluated in humans. Situations in which the risk of gallstone formation is high and well-defined lend themselves to the prospective study of gallstone pathophysiology. It is likely that the study of the process of gallstone formation in humans at high risk would lead to effective prevention strategies, and thus, eliminate the substantial morbidity associated with the formation of gallstones. Studies that would better define the risk of gallstones in high risk populations are also encouraged. In addition, clinical trials that address safe and cost-effective measures for the prevention of gallstones are encouraged. For clinical trials, administrative suggestions for preparing an R01 clinical trial grant application are available (see INQUIRIES). INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy that women and members of minority groups and their subpopulations must be included in all NIH supported biomedical and behavioral research projects involving human subjects, unless a clear compelling rationale and justification is provided that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43) and supersedes and strengthens the previous policies (Concerning the Inclusion of Women in Study Populations, and Concerning the Inclusion of Minorities in Study Populations), which have been in effect since 1990. The new policy contains some provisions that are substantially different from the 1990 policies. All applications proposing research involving human subjects should read the "NIH Guidelines for Inclusion of Women and Minorities as subjects in Clinical Research" that were published in the Federal Register of March 28, 1994 (FR 59 14508-14513) and reprinted in the NIH Guide for Grants and Contracts, Volume 23, Number 11, March 18, 1994. Investigators also may obtain copies of the policy from the program staff listed under INQUIRIES. Program staff may also provide additional relevant information concerning the policy. APPLICATION PROCEDURES Applications are to be submitted on the grant application form PHS 398 (rev. 5/95). Application kits are available at most institutional offices of sponsored research and may be obtained from the Office of Grants Information, Division of Research Grants, 6701 Rockledge Drive Suite 3032, MSC 7762, Bethesda, MD 20892-7762, telephone 301/435-0714. The title and number of this program announcement must be typed in Section 2 on the face page of the application. For investigators applying for support through the FIRST award mechanisms (R29), three letters of references must be submitted with the application. An applicant submitting a revised application in response to this RFA must again submit reference letters. Applications will be accepted at the regular application deadlines as indicated in the application kit. The receipt dates for applications for AIDS-related research are also found in the PHS 398 instructions. The completed original application and five legible copies must be sent or delivered to: OFFICE OF GRANTS INFORMATION DIVISION OF RESEARCH GRANTS NATIONAL INSTITUTES OF HEALTH 6701 ROCKLEDGE DRIVE, SUITE 1040 - MSC 7710 BETHESDA, MD 20892-7710 BETHESDA, MD 20817 (For express/courier service) REVIEW CONSIDERATIONS Applications will be assigned on the basis of established PHS referral guidelines. Applications will be reviewed for scientific and technical merit in accordance with the standard NIH peer review procedures. Following scientific-technical review, the applications will receive a second-level review by the appropriate national advisory council. Review Criteria o scientific, technical, or medical significance and originality of proposed research; o appropriateness and adequacy of the experimental approach and methodology proposed to carry out the research; o qualifications and research experience of the Principal Investigator and staff, particularly, but not exclusively, in the area of the proposed research; o availability of the resources necessary to perform the research; o appropriateness of the proposed budget and duration in relation to the proposed research; o adequacy of plans to include both sexes and minorities and their subgroups as appropriate for the scientific goals of the research. Plans for the recruitment and retention of subjects will also be evaluated. AWARD CRITERIA For other than clinical trials, applicants must limit their R01 requests to not more than $150,000 in direct costs for the first year budget period. For clinical trials the direct cost may not exceed $500,000 for the first budget period. Applications will compete for available funds with all other approved applications. The following will be considered in making funding decisions: o Quality of the proposed project as determined by peer review o Availability of funds o Program priority INQUIRIES Inquiries are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. For clinical trials, administrative suggestions for preparing an R01 clinical trial grant application are available. Direct inquiries regarding programmatic issues to: James Everhart, M.D., M.P.H. Division of Digestive Diseases and Nutrition National Institute of Diabetes and Digestive and Kidney Diseases Natcher Building, Room 6AN-12J 45 Center Drive MSC 6600 Bethesda, MD 20892-6600 Telephone: (301) 594-8878 FAX: (301) 480-8300 Email: vjy@cu.nih.gov Direct inquiries regarding fiscal matters to: Mrs. Thelma Jones Grants Management Branch National Institute of Diabetes and Digestive and Kidney Diseases Natcher Building, Room 6AS-44B 45 Center Drive MSC 6600 Bethesda, MD 20892-6600 Telephone: (301) 594-8853 FAX: (301) 480-3504 Email: jonest@ep.niddk.nih.gov AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.848. Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. The PHS strongly encourages all grant and contract recipients to provide a smoke-free workplace and promote the non-use of all tobacco products. In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routine education, library, day care, health care or early childhood development services are provided to children. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people. From owner-sci-resources@net.bio.net Wed Sep 06 23:00:00 1995 Path: biosci!biosci!not-for-mail From: BIOSCI Administrator Newsgroups: bionet.sci-resources Subject: NIH GUIDE - PA-95-087 - V24(32) 09/01/95 Date: 6 Sep 1995 19:14:47 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 302 Sender: biohelp@net.bio.net Approved: biosci-moderator@net.bio.net Distribution: world Message-ID: <42lkin$dj1@net.bio.net> NNTP-Posting-Host: net.bio.net $$XID RFA PA95087 PA-95-087 P1O1 *************************************** METABOLIC ENGINEERING NIH GUIDE, Volume 24, Number 32, September 1, 1995 PA NUMBER: PA-95-087 P.T. 34; K.W. 0765020, 1002019, 1002004, 0710055 National Institute of General Medical Sciences National Institute of Diabetes and Digestive and Kidney Diseases PURPOSE The purpose of this program announcement (PA) is to encourage research that will expand the conceptual and experimental basis of metabolic engineering. Basic research that contributes to a quantitative understanding of the integration and control of genetic, catalytic, and transport processes that comprise metabolism is encouraged, as is research to create techniques that facilitate the exploitation of metabolic processes for biomedical uses. ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic and foreign, for-profit and non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of State and local governments, eligible agencies of the Federal government. Applications from minority individuals and women are particularly encouraged. Foreign institutions are not eligible to receive First Independent Research Support and Transition (FIRST) awards (R29) or program project grants (P01). MECHANISM OF SUPPORT Support of this research will be through the individual research project grant (R01), program project grant (P01), FIRST Award (R29). Potential applicants for program project grants are strongly urged to contact the program staff listed under INQUIRIES for guidance concerning both the organization and scope of the proposed work and the preparation of the application itself. RESEARCH OBJECTIVES The study of intermediary and secondary metabolism at one time was the centerpiece of biochemistry and cellular physiology. This endeavor provided one of the first examples that cellular processes could be understood in molecular terms; it also brought into sharp relief the importance of enzymes as critical mediators of cellular activities. Despite the successes of decades of investigations of cellular metabolism, there still appears to be a vast amount to be learned about metabolism. While it is true that the enzymological sequences and intermediates of many metabolic pathways in a small number of well-studied organisms are known with some confidence, little is known in quantitative terms of the controls and integration of these pathways. Hence, it is difficult to predict rigorously the responses of metabolism to environmental changes and shifts in developmental programs. Investigations of these facets of intermediary and secondary metabolism are hampered by an inability to examine intracellular metabolite concentrations and enzyme activities in vivo, and by a lack of adequate analytical models to organize and describe the data. It is also clear that there is limited knowledge of the range of extant metabolic potential. There are vast numbers of organisms that have never been examined metabolically; some of these, such as the archaebacteria, various anaerobic bacteria, and marine microbes may utilize metabolic systems that are biochemically fascinating and potentially useful. An emerging approach to the understanding and exploitation of metabolic processes is metabolic (or pathway) engineering. As the name implies, metabolic engineering is the targeted and purposeful manipulation of the pathways of an organism. Metabolic engineering typically involves the alteration of cellular activities by the manipulation of the enzymatic, transport, and regulatory functions of the cell through the use of recombinant DNA and other genetic techniques. Much of this effort has focussed on microbial organisms, but important work is being done in plants, and cultured cells from both plants and animals. The prospects for successful metabolic engineering can be seen in two areas. On the one hand, it can be used to create a microbial or plant-based production route for useful quantities of "small" molecules, such as amino acids and other nutritionally important molecules, antineoplastics, various antibiotics (or their derivatives) and other valuable secondary metabolites. On the other hand, metabolic engineering can also provide a route to targeted metabolic changes useful in the exploration of the control architecture that integrates the genetic and catalytic processes in both normal and aberrant cells. While this latter approach is widely used already in contemporary cell biology, the systems-oriented, quantitative tools of metabolic engineering could provide access to an understanding of metabolic pathways that is significantly more amenable to mathematical analysis and modelling. The purpose of this program announcement is to promote investigations into the nature of metabolism, its control and its biomedically useful exploitation. Through this program announcement the National Institute of General Medical Sciences (NIGMS) is encouraging the submission of applications for grants to support research into such topics as the following: o the control mechanisms and the determinants of flux for pathways where these factors are not well understood; o the development and application of analytical instrumentation and techniques to study quantitatively the in vivo behavior of metabolic enzymes and regulatory molecules; o the identification of additional genetic tools, e.g., selective markers, reporter genes, vectors, and regulatory molecules for the introduction of targeted synthetic or regulatory capacity into host cells; o the creation of a broader range of host cells for the introduction of heterologous genes; o the enhancement of techniques for maintaining the viability and genetic stability of engineered cells; o databases and computational tools for pathway analysis that would facilitate quantitative modelling of metabolism; o the development of an improved understanding of the determinants of small molecule transport; o the exploration of systems showing potentially novel metabolic capacities, such as plants and diverse microbes. This listing is not meant to be all-inclusive. There are, no doubt, many areas of research, not specified above, that could contribute to both an expanded understanding of metabolic processes and a substantial broadening of their utilization for biomedical ends. It is expected that some of the research projects proposed in these areas would rely on collaboration between investigators from different disciplines -- biochemistry and chemical engineering, for example. Such collaborations, where two or more approaches can enhance the likelihood of success, would be welcome, but are not required. APPLICATION PROCEDURES Applications are to be submitted on the grant application form PHS 398 (rev. 5/95) and will be accepted at the standard application deadlines as indicated in the application kit. Application kits are available at most institutional offices of sponsored research and may be obtained from the Office of Grants Information, Division of Research Grants, National Institutes of Health, 6701 Rockledge Drive, Room 3032, MSC 7762, Bethesda, MD 20892, telephone (301) 435-0714. The title and number of this program announcement must be typed in Section 2 on the face page of the application (i.e., "Metabolic Engineering," PA-95-). For investigators applying for support through the FIRST Award mechanism (R29), three letters of reference must be submitted with the application attached to the face page. FIRST (R29) award applications submitted without the required number of reference letters will be considered incomplete and will be returned without review. An applicant submitting a revised application in response to this program announcement must again submit reference letters. The completed original application and five legible copies must be sent or delivered to: OFFICE OF GRANTS INFORMATION DIVISION OF RESEARCH GRANTS NATIONAL INSTITUTES OF HEALTH 6701 ROCKLEDGE DRIVE, ROOM 1040 - MSC 7710 BETHESDA, MD 20892-7710 BETHESDA, MD 20817 (for express/courier service) REVIEW CONSIDERATIONS Applications will be assigned on the basis of established PHS referral guidelines. Applications that are complete will be evaluated for scientific and technical merit by an appropriate peer review group convened in accordance with the standard NIH peer review procedures. As part of the initial merit review, all applications will receive a written critique and undergo a process in which only those applications deemed to have the highest scientific merit, generally the top half of applications under review, will be discussed, assigned a priority score, and receive a second level review by the appropriate national advisory council or board. Review Criteria o scientific, technical, or medical significance and originality of proposed research; o appropriateness and adequacy of the experimental approach and methodology proposed to carry out the research; o qualifications and research experience of the Principal Investigator and staff, particularly, but not exclusively, in the area of the proposed research; o availability of the resources necessary to perform the research; o appropriateness of the proposed budget and duration in relation to the proposed research; o adequacy of plans to include both sexes and minorities and their subgroups as appropriate for the scientific goals of the research. Plans for the recruitment and retention of subjects will also be evaluated. The initial review group will also examine the provisions for the protection of human and animal subjects, the safety of the research environment, and conformance with the NIH Guidelines for the Inclusion of Women and Minorities as Subjects in Clinical Research. AWARD CRITERIA Applications will compete for available funds with all other approved applications. The following will be considered in making funding decisions: o quality of the proposed project as determined by peer review; o availability of funds; o program priority of research in the area of the program announcement and other areas of Institute or Center interest. INQUIRIES Inquiries are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Direct inquiries regarding programmatic issues to: Warren Jones, Ph.D. Division of Pharmacology, Physiology, and Biological Chemistry National Institute of General Medical Sciences 45 Center Drive, MSC 6200 Bethesda, MD 20892-6200 Telephone: (301) 594-5938 FAX: (301) 480-2802 Email: JONESW@gm1.nigms.nih.gov James Anderson, Ph.D. Division of Genetics and Developmental Biology National Institute of General Medical Sciences 45 Center Drive, MSC 6200 Bethesda, MD 20892-6200 Telephone: (301) 594-0943 FAX: (301) 480-2228 Email: ANDERSOJ@gm1.nigms.nih.gov Catherine McKeon, Ph.D. Division of Diabetes, Endocrinology and Metabolic Diseases National Institute of Diabetes and Digestive and Kidney Diseases Natcher Building, Room 5AN-18B 45 Center Drive, MSC 6600 Bethesda, MD 20892-6600 Telephone: (301) 594-8810 FAX: (301) 480-3503 Email: McKeonC@ep.niddk.nih.gov Direct inquiries regarding fiscal matters to: Ms. Ruth Monaghan Grants Management Office National Institute of General Medical Sciences 45 Center Drive, MSC 6200 Bethesda, MD 20892-6200 Telephone: (301) 594-5135 FAX: (301) 594-2554 Email: MONAGHAR@gm1.nigms.nih.gov Ms. Donna Huggins Grants Management Branch National Institute of Diabetes and Digestive and Kidney Diseases Natcher Building, Room 6AN-49K 45 Center Drive, MSC 6600 Bethesda, MD 20892-6600 Telephone: (301) 594-8848 FAX: (301) 480-3504 Email: HugginsD@ep.niddk.nih.gov AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance Numbers 93.821, 93.847, 93.859, and 93.862. Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC 285c-8 and 285k) and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. The PHS strongly encourages all grant and contract recipients to provide a smoke-free workplace and promote the non-use of all tobacco products. In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routine education, library, day care, health care or early childhood development services are provided to children. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people. From owner-sci-resources@net.bio.net Sun Sep 24 23:00:00 1995 Path: biosci!biosci!not-for-mail From: maryh@foresnt.com Newsgroups: bionet.sci-resources Subject: DoD SBIR Fast Track Date: 25 Sep 1995 16:10:10 -0700 Organization: InterServ News Service Lines: 29 Sender: biohelp@net.bio.net Approved: biosci-moderator@net.bio.net Distribution: world Message-ID: <43uut7$krf@data.interserv.net> NNTP-Posting-Host: net.bio.net Hi, we are under contract with the Department of Defense. They asked us to send this message to small businesses and technology companies who would be interested in additional funding of their projects. DEFENSE DEPARTMENT TO AUGMENT PRIVATE SECTOR INVESTMENTS IN SBIR AWARD WINNERS DoD's Small Business Innovation Research (SBIR) program expects to fund $450 million in early-stage R&D projects at small technology companies in the next fiscal year, in technology areas that fall within the broad DoD mission. Starting this fall, DoD will give its highest priority in making SBIR awards to small companies that are able to attract independent third-party investors (such as venture capital firms, large companies, or "angel" investors). If selected for award, these small companies will receive uninterrupted DoD funding of up to $850,000 over a two-and-a-half year period. In practice, this means that an investor that offers to help fund an early-stage technology project at a small company can obtain a match of between $1 and $4 in DoD SBIR funds for every $1 the investor puts in. This new policy -- the SBIR "Fast Track" -- was approved for implementation by Under Secretary of Defense (Acquisition & Technology) Dr. Paul Kaminski in early June. Its purpose is to significantly increase DoD's success in converting SBIR research into affordable, high-performance products which serve military and commercial customers. For more information, see the file entitled "DoD SBIR Fast Track" on the World Wide Web page http://www.seeport.com/SBIR/fasttrk.htm, or call 1-800-382-4634." From owner-sci-resources@net.bio.net Sun Sep 24 23:00:00 1995 Path: biosci!biosci!not-for-mail From: Ray Dobert Newsgroups: bionet.sci-resources Subject: Solicitation Announcement Biotech. Grants Program (fwd) Date: 25 Sep 1995 16:18:48 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 412 Sender: biohelp@net.bio.net Approved: biosci-moderator@net.bio.net Distribution: world Message-ID: <447dco$k0p@net.bio.net> NNTP-Posting-Host: net.bio.net FYI CONTACT Dr. Edward K. Kaleikau ONLY for more info.(ekaleikau@reeusda.gov) Ray Dobert, Biotech Info Center,NAL/ARS/USDA ---------- Forwarded message ---------- Date: Tue, 19 Sep 1995 07:50:48 EST From: Gary L. Jensen Subject: Solicitation Announcement Biotech. Grants Program September 19, 1995 A Federal Register notice on the solicitation announcement for applications with the USDA grants program on Biotechnology Risk Assessment Research. Please share this notice with others who may have an interest in submitting a proposal. The deadline for receipt of proposals is December 11, 1995. Gary Jensen DEPARTMENT OF AGRICULTURE (USDA) Agricultural Research Service (ARS) Cooperative State Research Service Extension Service DEPARTMENT OF EDUCATION Purpose: Biotechnology Risk Assessment Research Grants Program; Fiscal Year 1996; Solicitation of Applications *Notices* (FEDREGISTER 60 FR 47236 09/11/95; 413 lines.) DEPARTMENT OF AGRICULTURE Agricultural Research Service; Cooperative State Research, Education and Extension Service Biotechnology Risk Assessment Research Grants Program; Fiscal Year 1996; Solicitation of Applications Purpose: Applications are invited for competitive grant awards under the Biotechnology Risk Assessment Research Grants Program (the "Program") for fiscal year 1996. The authority for the Program is contained in section 1668 of Pub. L. No. 101-624 (the Food, Agriculture, Conservation, and Trade Act of 1990, 7 U.S.C. 5921). The Program is administered by the Cooperative State Research, education and Extension Service (CSREES) and the Agricultural Research Service (ARS) of the U.S. Department of Agriculture. The purpose of the Program is to assist Federal regulatory agencies in making science-based decisions about the safety of introducing genetically modified plants, animals, and microorganisms into the environment. The Program accomplishes this purpose by providing scientific information derived from the risk assessment research conducted under it. Research proposals submitted to the Program must be applicable to the purpose of the Program to be considered. Awards will not be made for clinical trials, commercial product development, product marketing strategies, or other research not appropriate to risk assessment. Applicant Eligibility: Proposals may be submitted by any United States public or private research or educational institution or organization. Available Funding: Subject to the availability of funds, the anticipated amount available for support of the program in fiscal year 1996 is $ 1.7 million. It is expected that Congress, in the final version of the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 1996 (H.R. 1976), will prohibit CSREES from using the funds available for fiscal year 1996 to pay indirect costs exceeding 14 per centum of the total Federal funds provided under each award on competitively-awarded research grants. In addition, it is expected that, pursuant to the final version of the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 1996 (H.R. 1976), in the case of any equipment or product that may be authorized to be purchased with the funds provided under this Program, entities will be encouraged to use such funds to purchase only American-made equipment or products. Program Description: Under the Program, USDA will competitively award research grants to support science-based biotechnology regulation and thus help address concerns about the effects of introducing genetically modified organisms into the environment and to help regulators develop policies concerning such introduction. Proposals are invited in the area of biotechnology risk assessment research as appropriate to agricultural plants, animals and microbes. Proposals based upon field research and whole organism-population level studies are strongly encouraged. Although emphasis will be given to risk assessment research involving genetically modified organisms, model systems using nongenetically modified organisms also will be considered if they can provide information that could lead to improved assessment of potential risks associated with the introduction of genetically modified organisms into the environment. Proposals should be applicable to current regulatory issues surrounding the ecological impacts of genetically modified organisms. Proposal Evaluation: Proposals will be evaluated by the administrator assisted by a peer panel of scientists for scientific merit, qualifications of project personnel, adequacy of facilities, and relevance for current regulatory issues. Areas of Research to be Supported in Fiscal Year 1996: Proposals addressing the following research topics are requested: 1. Development of new risk assessment methods (e.g., monitoring organism escape, measuring biological impacts), and risk assessment procedures (e.g. comparative analysis of ecosystems, models to predict risks) that could be used in risk assessment of genetically modified fungi, bacteria, viruses (including animal vaccines), plants, arthropods, fish, birds, and mammals. Applicants should address the need for, and development of, new risk assessment methods in the course of addressing a specific and defined risk assessment issue, especially as pertains to genetically modified organisms. The development of better risk assessment methods for field testing genetically modified organisms also will be considered. 2. Creation of information systems and computer models to support regulatory agency decision-making in regards to potential impacts to the environment over time (e.g., computer models to describe the interaction of environmental and organismal factors especially for establishment and dispersal of the organism). 3. Risk assessment of the environmental fate (e.g. survival, reproductive fitness, genetic stability, horizontal gene transfer) as correlated with effects (e.g., loss of genetic diversity, enhanced competition) of genetically modified fungi, bacteria, viruses, plants, arthropods, fish, birds, and mammals introduced into the environment (i.e., not in a contained laboratory, greenhouse or building); and studies or identification of traits which may influence fate and effects. In response to requests to Program Directors and Federal regulatory agencies, as stipulated in the authorizing legislation for the Program, section 1668 of Public Law 101-624, the following specific areas of risk assessment research have been identified as eligible for competition as research topics for this year: 4. The bidirectional rates, effects of selection pressures, mechanisms and impact of gene transfer between currently genetically transformable crop species and existing North American weedy, free living relatives of those crops including studies of methods of mitigation of potential gene exchange. Research could rely on reanalysis of published information and/or laboratory/field studies. 5. The potential for recombination between plant viruses and plant- encoded noncapsid viral genes (e.g. replicase), especially for those viruses in supergroup B (carmovirus, tombusvirus, luteovirus, sobemovirus). Such studies should identify recombination potentials and, if demonstrated, define frequencies and effect on symptom expression. Comparisons with recombination frequencies between naturally occurring viral sequences are encouraged. 6. Changes in viral host ranges or the types of viral vectors as a result of the use of transgenic plants expressing viral genes. 7. The potential for nontarget effects of introduced plant-defense compounds expressed in genetically modified plant-associated microorganisms (e.g., compounds in phyllosphere or rhizosphere- inhabiting bacteria) or in plants (e.g., Bacillus thuringiensis delta-endotoxin), especially in regard to persistence of the organisms and material in the environment. [p47237] 8. Identification of genes which can confer additional pathogenicity to animal pathogens. 9. Environmental risk analysis of large scale deployment of genetically engineered organisms; especially commercial uses of such organisms, with special reference to consideration that may not be revealed through small scale evaluations and tests. All research proposals submitted should include a statement describing the relevance of the proposed project to one or more of the research topics requested. When appropriate, detailed descriptions of statistical analyses to be done should be included in the proposal. The inclusion of statisticians as co-principal investigators or contractors is encouraged. Note: Individual investigators whose research projects are funded under the Program will be required to attend, present data and provide a manuscript on the results of their research at an Annual Conference. Attendance costs at such a conference do not need to be included in the budgets of proposed research projects; such costs will be paid from funds provided under a cooperative agreement between CSREES and the University of Maryland for an annual risk assessment symposium Additionally, a final project report on research results will be required in a fixed protocol, electronic format, suitable for distribution by USDA. Applicable Regulations: This Program is subject to the administrative provisions found in 7 CFR part 3415 (58 FR 65646, December 15, 1993), which set forth procedures to be followed when submitting grant proposals, rules governing the evaluation of proposals, the awarding of grants, and post-award administration of such grants. Several other Federal statutes and regulations apply to grant proposals considered for review or to grants awarded under this Program. These include, but are not limited to: 7 CFR Part 1.1-USDA implementation of the Freedom of Information Act; 7 CFR Part 1c-USDA implementation of the Federal Policy for the Protection of Human Subjects; 7 CFR Part 3-USDA implementation of OMB Circular A-129 regarding debt collection; 7 CFR Part 15, Subpart A-USDA implementation of Title VI of the Civil Rights Act of 1964; 7 CFR Part 520-ARS implementation of the National Environmental Policy Act; 7 CFR Part 3015-USDA Uniform Federal Assistance Regulations, implementing OMB directives (i.e., Circular Nos. A-110, A-21, and A- 122) and incorporating provisions of 31 U.S.C. 6301-6308 (formerly, the Federal Grant and Cooperative Agreement Act of 1977, Pub. L. No. 95-224), as well as general policy requirements applicable to recipients of Departmental financial assistance; 7 CFR Part 3016-USDA Uniform Administrative Requirements for Grants and Cooperative Agreements to State and Local Governments; 7 CFR Part 3017, as amended-USDA implementation of Governmentwide Debarment and Suspension (Nonprocurement) and Governmentwide Requirements for Drug-Free Workplace (Grants); 7 CFR Part 3018-USDA implementation of New Restrictions on Lobbying. Imposes new prohibitions and requirements for disclosure and certification related to lobbying on recipients of Federal contracts, grants, cooperative agreements, and loans; 7 CFR Part 3051-Audits of Institutions of Higher Education and Other Nonprofit Institutions; 7 CFR Part 3407-CSREES implementation of the National Environmental Policy Act; 29 U.S.C. 794, section 504-Rehabilitation Act of 1973, and 7 CFR Part 15B (USDA implementation of the statute), prohibiting discrimination based upon physical or mental handicap in federally assisted programs; 35 U.S.C. 200 et seq.-Bayh-Dole Act, controlling allocation of rights to inventions made by employees of small business firms and domestic nonprofit organizations, including universities, in Federally assisted programs (implementing regulations are contained in 37 CFR part 401). Programmatic Contact: For additional information on the Program, please contact: Dr. Edward K. Kaleikau, Cooperative State Research, Education, and Extension Service, U.S. Department of Agriculture, Ag Box 2241, Washington, DC 20250-2241, Telephone: (202) 401-1901 or Dr. Robert M. Faust, Agricultural Research Service, U.S. Department of Agriculture, Room 338, Building 005, BARC-West, Beltsville, MD 20705, Telephone: (301) 504-6918. How to Obtain Application Materials: Copies of this solicitation, the administrative provisions for the Program (7 CFR Part 3415), and the Application Kit contains required forms, certifications, and instructions for preparing and submitting grant applications. The administrative provisions include guidelines for proposal format. Copies of this solicitation, the administrative provisions, and the Application Kit may be obtained by contacting: Proposal Services Branch, Awards Management Division, Cooperative State Research, Education and Extension Service, U.S. Department of Agriculture, Ag Box 2245, Washington, DC 20250-2245, Telephone Number: (202) 401-5048 Application materials may also be requested via Internet by sending a message with your name, mailing address (not e-mail) and telephone number psb@reeusda.gov which states that you wish to receive a copy of the application materials for the Fiscal Year 1996 Biotechnology Risk Assessment Research Grants Program. The materials will then be mailed to you (not e-mailed) as quickly as possible. Proposal Format: The format guidelines for full research proposals, found in the administrative provisions for the Program at Sec. 3415.4(d), should be followed for the preparation of proposals under the Program in fiscal year 1996. (Note that the Department elects not to solicit preproposals nor conference grant proposals in fiscal year 1996.) Compliance with the National Environmental Policy Act (NEPA) As outlined in 7 CFR part 3407 and 7 CFR part 520 (the CSREES and ARS regulations implementing the National Environmental Policy Act of 1969), environmental data for any proposed project is to be provided to CSREES and ARS so that CSREES and ARS may determine whether any further action is needed. The applicant shall review the following categorical exclusions and determine if the proposed project may fall within one of the categories. (1) Department of Agriculture Categorical Exclusions (7 CFR 1b.3) (i) Policy development, planning and implementation which are related to routine activities such as personnel, organizational changes, or similar administrative functions; (ii) Activities which deal solely with the funding of programs, such as program budget proposals, disbursements, and transfer or reprogramming of funds; [p47238] (iii) Inventories, research activities, and studies, such as resource inventories and routine data collection when such actions are clearly limited in context and intensity; (iv) Educational and informational programs and activities; (v) Civil and criminal law enforcement and investigative activities; (vi) Activities which are advisory and consultative to other agencies and public and private entities; and (vii) Activities related to trade representation and market development activities abroad. (2) CSREES and ARS Categorical Exclusions (7 CFR 3407.6 and 7 CFR 520.5) Based on previous experience, the following categories of CSREES and ARS actions are excluded because they have been found to have limited scope and intensity and to have no significant individual or cumulative impacts on the quality of the human environment: (i) The following categories of research programs or projects of limited size and magnitude or with only short-term effects on the environment: (A) Research conducted within any laboratory, greenhouse, or other contained facility where research practices and safeguards prevent environmental impacts; (B) Surveys, inventories, and similar studies that have limited context and minimal intensity in terms of changes in the environment; and (C) Testing outside of the laboratory, such as in small isolated field plots, which involves the routine use of familiar chemicals or biological materials. (ii) Routine renovation, rehabilitation, or revitalization of physical facilities, including the acquisition and installation of equipment, where such activity is limited in scope and intensity. In order for CSREES and ARS to determine whether any further action is needed with respect to NEPA, pertinent information regarding the possible environmental impacts of a particular project is necessary; therefore, a separate statement must be included in the proposal indicating whether the applicant is of the opinion that the project falls within a categorical exclusion and the reasons therefor. If it is the applicant's opinion that the project proposed falls within the categorical exclusions, the specific exclusions must be identified. The information submitted shall be identified as "NEPA Considerations" and the narrative statement shall be placed after the coversheet of the proposal. Even though a project may fall within the categorical exclusions, CSREES and ARS may determine that an Environmental Assessment or an Environmental Impact Statement is necessary for an activity, if substantial controversy on environmental grounds exists or if other extraordinary conditions or circumstances are present which may cause such activity to have a significant environmental effect. Proposal Submission: What to Submit An original and 14 copies of a proposal must be submitted. Each copy of each proposal must be stapled securely in the upper lefthand corner (DO NOT BIND). All copies of the proposal must be submitted in one package. Where and When to Submit: Proposals must be received by 4:30 p.m. eastern standard time on December 11, 1995. Proposals sent by First Class mail must be sent to the following address: Proposal Services Branch, Awards Management Division, Cooperative State Research, Education, and Extension Service, U.S. Department of Agriculture, Ag Box 2245, Washington, DC 20250-2245, Telephone: (202) 401-5048 Proposals that are delivered by Express mail, a courier service, or by hand must be submitted to the following address (note that the zip code differs from that shown above): Proposal Services Branch, Awards Management Division, Cooperative State Research, Education and Extension Service, U.S. Department of Agriculture, Room 303, Aerospace Center, 901 D Street, SW., Washington, DC 20024, Telephone: (202) 401- 5048 Supplementary Information: The Biotechnology Risk Assessment Research Grants Program is listed in the Catalog of Federal Domestic Assistance under No. 10.219. For reasons set forth in the final rule-related Notice to 7 CFR Part 3015, subpart V (48 FR 29115, June 24, 1983), this Program is excluded from the scope of Executive Order No. 12372 which requires intergovernmental consultation with State and local officials. Under the provisions of the Paperwork Reduction Act of 1980 (44 U.S.C. 3504(h)), the collection of information requirements contained in this Notice have been approved under OMB Document No. 0524-0022. Done at Washington, DC, on this 1st day of September, 1995. William D. Carlson, Acting Administrator, Cooperative State Research, Education, and Extension Service. Robert J. Reginato, Acting Administrator, Agricultural Research Service. [FR Doc. 95-22464 Filed 9-8-95; 8:45 am] From owner-sci-resources@net.bio.net Mon Sep 25 23:00:00 1995 Path: biosci!biosci!not-for-mail From: BIOSCI Administrator Newsgroups: bionet.sci-resources Subject: NIH Guide, vol. 24, no. 33, pt. 2of2, 22 September 1995 Date: 25 Sep 1995 21:54:17 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 230 Sender: biohelp@net.bio.net Approved: biosci-moderator@net.bio.net Distribution: world Message-ID: <44811p$bbr@net.bio.net> NNTP-Posting-Host: net.bio.net $$XID NIHGUIDE 19950922 V24N33 P2O2 ************************************ INQUIRIES The RFA, which describes the research objectives, application procedures, review considerations and award criteria for this solicitation, may be obtained electronically through the NIH Grant Line (data line 301-402-2221) and the NIH GOPHER (gopher.nih.gov), and by email from the program contact listed below. Ralph L. Bain, Ph.D. Division of Kidney, Urologic, and Hematologic Diseases National Institute of Diabetes and Digestive and Kidney Diseases 45 Center Drive, MSC 6600 Bethesda, MD 20892-6600 Telephone: (301) 594-7717 FAX: (301) 480-3510 Email: bainr@ep.niddk.nih.gov $$R11 END *********************************************************** $$P1 BEGIN PA-95-089 FULL-TEXT ************************************** CLINICAL NEUROSCIENCE OF DRUG ABUSE AND ADDICTION NIH GUIDE, Volume 24, Number 33, September 22, 1995 PA AVAILABLE: PA-95-089 P.T. 34; K.W. 1002030, 0404001, 0404009, 0710085, 0710100 National Institute on Drug Abuse PURPOSE Rapid advances in brain imaging, neurophysiological assessment, and genome analysis have made feasible the study of biological etiology of drug abuse, dependency, and addiction. New technology has also facilitated assessment of the biomedical and biobehavioral consequences, as well as the effects of treatment of drug abuse disorders. The National Institute on Drug Abuse (NIDA) is supporting a major neuroscience initiative that targets newly developing technologies designed for study of human subjects, autopsy material, or, in appropriate circumstances, animal models. The goal is to better understand the etiology and neurobiological consequences of drug abuse and addiction in order to design novel preventive, diagnostic, and treatment strategies. The NIDA invites applications to use current, or to develop new, noninvasive techniques to assess neuroanatomical, neurophysiological, neurochemical, or functional differences in human brain that (1) result from consequences of drug use; (2) indicate individuals' vulnerabilities (or resistances) to initiate and escalate drug use into abuse, dependence or addiction; or (3) result from pharmacological or non-pharmacological treatment. Applications are also encouraged to establish integrated, multidisciplinary programs that include both basic research and clinical studies. Support mechanisms for this program announcement are the research project grant (R01), program project grant (P01), First Independent Research Support and Transition (FIRST) Award (R29), exploratory/developmental grant (R21) and small grants (R03). HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of Healthy People 2000, a PHS-led national activity for setting priority areas. This program announcement, Human Basic and Clinical Neuroscience of Drug Addiction, is related to the priority areas of tobacco, alcohol and other drugs, and maternal and infant health. Potential applicants may obtain a copy of Healthy People 2000 (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-512-1800). INQUIRIES The PA, which describes the research objectives, application procedures, review considerations, and award criteria for this solicitation, may be obtained electronically through the NIH Grant Line (data line 301/402-2221) and the NIH GOPHER (gopher.nih.gov), and by mail and email from the program contact listed below. Joseph Frascella, Ph.D. Division of Clinical and Services Research National Institute on Drug Abuse 5600 Fishers Lane, Room 10A-46 Rockville, MD 20857 Telephone: (301) 443-4877 FAX: (301) 443-2317 Email: jfrascel@aoada.ssw.dhhs.gov Roger Brown, Ph.D. Division of Basic Research National Institute on Drug Abuse 5600 Fishers Lane, Room 10A-19 Rockville, MD 20857 Telephone: (301) 443-6975 Email: rbrown1@aoda.ssw.dhhs.gov $$P1 END ************************************************************ $$P2 BEGIN PA-95-090 FULL-TEXT ************************************** OLFACTORY NEUROGENESIS NIH GUIDE, Volume 24, Number 33, September 22, 1995 PA AVAILABLE: PA-95-090 P.T. 34; K.W. 0775017, 1002004, 0705048 National Institute on Deafness and Other Communication Disorders National Institute on Aging PURPOSE This program announcement reiterates the continuing interest of the National Institute on Deafness and Other Communication Disorders (NIDCD) and the National Institute on Aging (NIA) in receiving applications for the study of the mechanisms that maintain, terminate, and reinitiate the sequence of olfactory neurogenesis in the olfactory epithelium throughout the life of the organism. The scope of this program announcement includes the neurogenic sequence of cell proliferation, differentiation, synaptogenesis, growth, migration, maturation, cell death, and the mitotic signals to renew the cycle under both normal physiologic conditions and after experimental procedures, such as olfactory nerve transection, that perturb this unique cycle of neural development. This program announcement is timely because the recent development of molecular tools makes the identification of specific types of sensory neurons and their connections practical. This announcement supplements a previous one, Nasal Chemoreception: Regeneration and Trophic Interactions (NIH Guide, Vol. 18, No. 34, September 29, 1989), and is part of the NIDCD programmatic theme of sensory regeneration in the auditory, vestibular, and chemosensory systems. The support mechanisms for grants in this area will be the individual investigator-initiated research project grant (R01) and the First Independent Research Support and Transition (FIRST) (R29) award. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This Program Announcement, Olfactory Neurogenesis, is related to the priority areas of diabetes and chronic disabling conditions and special population objectives. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-11474-0 or Summary Report: Stock No. 017-001-11473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-512-1800). INQUIRIES The PA, which describes the research objectives, application procedures, review considerations, and award criteria for this program, may be obtained electronically through the NIH Grant Line (data line 301-402-2221) and the NIH GOPHER (gopher.nih.gov), and by mail and email from the program contact listed below. Jack Pearl, Ph.D. Division of Human Communication National Institute on Deafness and Other Communication Disorders Executive Plaza South, Room 400-C 6120 Executive Boulevard - MSC 7180 Bethesda, MD 20892-7180 Telephone: (301) 402-3464 FAX: (301) 402-6251 Email: Jack_Pearl@nih.gov $$P2 END ************************************************************ $$P3 BEGIN PAR-95-091 FULL-TEXT ************************************* CANCER PREVENTION AND CONTROL RESEARCH SMALL GRANT PROGRAM NIH GUIDE, Volume 24, Number 33, September 22, 1995 PA AVAILABLE: PAR-95-091 P.T. 34; K.W. 0715035, 0745027, 0795003, 0404000 National Cancer Institute PURPOSE The National Cancer Institute (NCI) invites applications for Small Research Grants (R03) in cancer prevention and control. This program is designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of research expertise in the field of human cancer control intervention research. New, as well as experi